July 13, 2009— The results of a preliminary clinical trial suggest that a new Alzheimer’s drug from Humanetics Corporation is safe for daily use and that cognitive performance in patients with mild to moderate disease remained stable during the six-week course of the trial. The lack of decline in cognitive performance was an encouraging finding to be further evaluated in a Phase IIB clinical trial. Phase IIA clinical findings were presented in Vienna at the 2009 Alzheimer’s Association International Conference on Alzheimer’s Disease (ICAD 2009) by investigators from The Mount Sinai School of Medicine (MSSM). The study was conducted at The Mount Sinai Alzheimer’s Disease Research Center in New York, a nationally renowned center of excellence since 1984 offering a comprehensive clinical program and research facility dedicated to the study and treatment of both normal aging and Alzheimer’s disease.Study investigators Giulio Pasinetti, M.D., Ph.D. and Hillel Grossman, M.D., both of Mount Sinai School of Medicine, each made a poster presentation on NIC5-15 at ICAD 2009. Dr. Pasinetti said his findings supported the conclusion that “NIC5-15 is a safe and tolerable natural compound that may alleviate Alzheimer’s disease dementia through multiple mechanisms including Abeta lowering activities. These early findings suggest the need for further investigation of NIC5-15 in the treatment of Alzheimer’s disease.”... Humanetics' Press Release -
